295 related articles for article (PubMed ID: 32935605)
21. Fibroblast growth factor receptors across urothelial carcinoma landscape.
Ertl IE; Shariat SF; Mostafaei H; Ilijazi D; Loriot Y
Curr Opin Urol; 2020 Jul; 30(4):557-565. PubMed ID: 32452999
[TBL] [Abstract][Full Text] [Related]
22. Clinical and Genomic Landscape of FGFR3-Altered Urothelial Carcinoma and Treatment Outcomes with Erdafitinib: A Real-World Experience.
Guercio BJ; Sarfaty M; Teo MY; Ratna N; Duzgol C; Funt SA; Lee CH; Aggen DH; Regazzi AM; Chen Z; Lattanzi M; Al-Ahmadie HA; Brannon AR; Shah R; Chu C; Lenis AT; Pietzak E; Bochner BH; Berger MF; Solit DB; Rosenberg JE; Bajorin DF; Iyer G
Clin Cancer Res; 2023 Nov; 29(22):4586-4595. PubMed ID: 37682528
[TBL] [Abstract][Full Text] [Related]
23. Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): an international, single-arm, phase 2 study.
Pant S; Schuler M; Iyer G; Witt O; Doi T; Qin S; Tabernero J; Reardon DA; Massard C; Minchom A; Lugowska I; Carranza O; Arnold D; Gutierrez M; Winter H; Stuyckens K; Crow L; Najmi S; Hammond C; Thomas S; Santiago-Walker A; Triantos S; Sweiti H; Loriot Y;
Lancet Oncol; 2023 Aug; 24(8):925-935. PubMed ID: 37541273
[TBL] [Abstract][Full Text] [Related]
24. An evaluation of the efficacy and safety of erdafitinib for the treatment of bladder cancer.
Nauseef JT; Villamar DM; Lebenthal J; Vlachostergios PJ; Tagawa ST
Expert Opin Pharmacother; 2020 Jun; 21(8):863-870. PubMed ID: 32124650
[TBL] [Abstract][Full Text] [Related]
25. Adipocyte Precursor-Derived NRG1 Promotes Resistance to FGFR Inhibition in Urothelial Carcinoma.
Hosni S; Kilian V; Klümper N; Gabbia D; Sieckmann K; Corvino D; Winkler A; Saponaro M; Wörsdörfer K; Schmidt D; Hahn O; Zanotto I; Bertlich M; Toma M; Bald T; Eckstein M; Hölzel M; Geyer M; Ritter M; Wachten D; De Martin S; Alajati A
Cancer Res; 2024 Mar; 84(5):725-740. PubMed ID: 38175774
[TBL] [Abstract][Full Text] [Related]
26. Targeting the FGFR Pathway in Urothelial Carcinoma: the Future Is Now.
Peng J; Sridhar S; Siefker-Radtke AO; Selvarajah S; Jiang DM
Curr Treat Options Oncol; 2022 Sep; 23(9):1269-1287. PubMed ID: 35962938
[TBL] [Abstract][Full Text] [Related]
27. Treatment approaches for FGFR-altered urothelial carcinoma: targeted therapies and immunotherapy.
Benjamin DJ; Hsu R
Front Immunol; 2023; 14():1258388. PubMed ID: 37675102
[TBL] [Abstract][Full Text] [Related]
28. Fibroblast growth factor receptor (
Al-Obaidy KI; Cheng L
J Clin Pathol; 2021 Aug; 74(8):491-495. PubMed ID: 33731335
[TBL] [Abstract][Full Text] [Related]
29. Fibroblast growth factor receptor inhibitor erdafitinib promotes Mcl-1 degradation and synergistically induces apoptosis with Bcl-xL/Bcl-2 inhibitor in urothelial cancer cells.
Ohtsu A; Arai S; Sawada T; Kato M; Maeno Y; Miyazawa Y; Fujizuka Y; Sekine Y; Koike H; Matsui H; Suzuki K
Biochem Biophys Res Commun; 2022 Nov; 628():76-83. PubMed ID: 36084554
[TBL] [Abstract][Full Text] [Related]
30. Discovery and Pharmacological Characterization of JNJ-42756493 (Erdafitinib), a Functionally Selective Small-Molecule FGFR Family Inhibitor.
Perera TPS; Jovcheva E; Mevellec L; Vialard J; De Lange D; Verhulst T; Paulussen C; Van De Ven K; King P; Freyne E; Rees DC; Squires M; Saxty G; Page M; Murray CW; Gilissen R; Ward G; Thompson NT; Newell DR; Cheng N; Xie L; Yang J; Platero SJ; Karkera JD; Moy C; Angibaud P; Laquerre S; Lorenzi MV
Mol Cancer Ther; 2017 Jun; 16(6):1010-1020. PubMed ID: 28341788
[TBL] [Abstract][Full Text] [Related]
31. Salvage systemic therapy for metastatic urothelial carcinoma: an unmet clinical need.
Montazeri K; Sonpavde G
Expert Rev Anticancer Ther; 2021 Mar; 21(3):299-313. PubMed ID: 33249937
[TBL] [Abstract][Full Text] [Related]
32. The role of fibroblast growth factor receptor (FGFR) protein-tyrosine kinase inhibitors in the treatment of cancers including those of the urinary bladder.
Roskoski R
Pharmacol Res; 2020 Jan; 151():104567. PubMed ID: 31770593
[TBL] [Abstract][Full Text] [Related]
33. The future of bladder cancer therapy: Optimizing the inhibition of the fibroblast growth factor receptor.
Morales-Barrera R; Suárez C; González M; Valverde C; Serra E; Mateo J; Raventos C; Maldonado X; Morote J; Carles J
Cancer Treat Rev; 2020 Jun; 86():102000. PubMed ID: 32203842
[TBL] [Abstract][Full Text] [Related]
34. Oncogenic Characterization and Pharmacologic Sensitivity of Activating Fibroblast Growth Factor Receptor (FGFR) Genetic Alterations to the Selective FGFR Inhibitor Erdafitinib.
Karkera JD; Cardona GM; Bell K; Gaffney D; Portale JC; Santiago-Walker A; Moy CH; King P; Sharp M; Bahleda R; Luo FR; Alvarez JD; Lorenzi MV; Platero SJ
Mol Cancer Ther; 2017 Aug; 16(8):1717-1726. PubMed ID: 28416604
[TBL] [Abstract][Full Text] [Related]
35. P4HA2-mediated HIF-1α stabilization promotes erdafitinib-resistance in FGFR3-alteration bladder cancer.
Li X; Li Y; Liu B; Chen L; Lyu F; Zhang P; He Q; Cheng L; Liu C; Song Y; Xing Y
FASEB J; 2023 Apr; 37(4):e22840. PubMed ID: 36943397
[TBL] [Abstract][Full Text] [Related]
36. Fibroblast Growth Factor Receptor (FGFR) Inhibitors in Urothelial Cancer.
Garje R; An J; Obeidat M; Kumar K; Yasin HA; Zakharia Y
Oncologist; 2020 Nov; 25(11):e1711-e1719. PubMed ID: 32790011
[TBL] [Abstract][Full Text] [Related]
37. A comprehensive overview of selective and novel fibroblast growth factor receptor inhibitors as a potential anticancer modality.
Jain NK; Tailang M; Thangavel N; Makeen HA; Albratty M; Najmi A; Alhazmi HA; Zoghebi K; Alagusundaram M; Jain HK; Chandrasekaran B
Acta Pharm; 2024 Mar; 74(1):1-36. PubMed ID: 38554385
[TBL] [Abstract][Full Text] [Related]
38. Case Report: Erdafitinib-induced Central Serous Chorioretinopathy.
Claiborne RT; Tsan GL
Optom Vis Sci; 2022 Jan; 99(1):88-92. PubMed ID: 34882600
[TBL] [Abstract][Full Text] [Related]
39. Erdafitinib (Balversa) for urothelial carcinoma.
Med Lett Drugs Ther; 2024 May; 66(1702):e83-e84. PubMed ID: 38696316
[No Abstract] [Full Text] [Related]
40. Biomarker-Oriented Therapy in Bladder and Renal Cancer.
Scholtes MP; Alberts AR; Iflé IG; Verhagen PCMS; van der Veldt AAM; Zuiverloon TCM
Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33799514
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]